A Unified Model of Cardiovascular Injury: How PANoptosis Connects Atherosclerotic Inflammation to Myocardial Death

Xin Zhang1, Mengdan Liu2, Yunyun Yang2

  • 1Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin University, Changchun, China.

Abstract

Insights

PANoptosis, a cell-death program, unifies cardiovascular diseases like atherosclerosis and heart failure by explaining shared inflammation and tissue damage mechanisms. This integrated view highlights immunometabolic triggers and cell-death pathways driving disease progression.

Area of Science:

  • Cardiovascular pathology
  • Cell death mechanisms
  • Immunometabolism

Background:

  • PANoptosis, combining pyroptosis, apoptosis, and necroptosis, is orchestrated by nucleic acid sensors like ZBP1, leading to multimodal cell death.
  • Endothelial PANoptosis is triggered by disturbed flow via Piezo1-Calpain signaling, involving mitochondrial dysfunction and mtDNA release.
  • Macrophage uptake of oxidized lipids and succinate-driven ROS bursts during reperfusion further promote PANoptosis and plaque instability.

Purpose of the Study:

  • To propose PANoptosis as a unifying mechanism in cardiovascular diseases, linking vascular and myocardial pathologies.
  • To elucidate the role of immunometabolic triggers and cell-death machinery in the athero-myocardial axis.
  • To differentiate co-activation from molecular shunting within PANoptosomes and clarify EV-mediated propagation.

Main Methods:

  • Review of emerging evidence on PANoptosis in cardiovascular pathology.
  • Analysis of upstream signaling pathways and molecular triggers.
  • Mapping of systemic feedback loops and therapeutic windows.

Main Results:

  • Vascular and myocardial injuries share core PANoptotic machinery but are linked by systemic feedback loops.
  • Co-activation of different cell death types within PANoptosomes needs careful distinction.
  • Extracellular vesicle (EV)-based propagation mechanisms are emerging but require further interpretation.

Conclusions:

  • Future cardiovascular disease strategies should focus on nanomedicine, metabolic reprogramming, and precise timing for interventions.
  • Understanding PANoptosis offers a new paradigm for treating atherosclerosis, ischemia-reperfusion injury, and heart failure.
  • Targeting shared cell-death pathways presents a promising therapeutic avenue across the athero-myocardial axis.

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Inflammation01:38

Inflammation

Overview
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...